Biologics represent a critical advancement in treating psoriasis, encompassing tumor necrosis factor-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors [51]. This evidence concerns the gene IL17A and psoriasis.